FDA’s regulatory science activities are working to advance the field of precision oncology, in part by using predictive analyses to identify patients that may be good candidates for certain therapies, according to Sean Khozin, MD, MPH, senior medical officer at the FDA.
FDA’s regulatory science activities are working to advance the field of precision oncology, in part by using predictive analyses to identify patients that may be good candidates for certain therapies, according to Sean Khozin, MD, MPH, senior medical officer at the FDA.
Transcript (slightly modified)
How does the FDA encourage advances in precision oncology?
If we look at the definition of precision oncology, as we all know we can best describe it as delivering the right drug to the right patient at the right dose. If you look at FDA’s approval mechanism, you’ll notice that the policies and procedures that have been put into place, in fact, are based on that very precise definition of precision medicine.
So in essence, when we review a marketing application, when we analyze the data, and do labeling negotiations, we ensure that the data supports the indication, the population of patients who are supposed to be treated, at the right dose. So that system has already been built into the approval process and the mechanism at the FDA.
Now, precision is a moving target and it’s driven by science. And it’s a very rapidly evolving field in oncology. Obviously, drugs are getting more targeted and more precise. So one of the ways, and one of the primary ways, that the FDA has been contributing to the advancement of the field is through its regulatory science activity. What we have been doing more, especially more in recent years, is looking at our own internal data and doing our own analyses, aggregated analyses on primary research to be able to identify for example populations of patients that may have certain characteristics that may make them a good candidate for certain types of therapies. We’re doing predictive analytics.
So that’s become part of the regulatory science process where we are doing primary research using our own data and also in collaboration with outside entities to contribute in a very proactive fashion to the advancement of the field of precision oncology.
Clinical Characteristics, Outcomes of Patients With Plaque Psoriasis on Tapinarof Cream
December 5th 2023Two posters presented at the 2023 Fall Clinical Dermatology Conference examined patient demographics, clinical characteristics, and outcomes in patients with plaque psoriasis treated with tapinerof cream.
Read More
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Imetelstat Offers Benefits for Patients With MDS Who Are Red Blood Cell–Transfusion Dependent
December 5th 2023The past year has offered new hope for patients with lower-risk myelodysplastic syndromes. Besides imetelstat, which has an FDA deadline for action of June 2024, the agency approved luspatercept, which has a different mechanism of action.
Read More